Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
- Conditions
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT03768063
- Locations
- 🇺🇸
Univ of Alabama at Birmingham; UAB Comprehensive Cancer Ctr, Birmingham, Alabama, United States
🇺🇸HonorHealth Research Institute - Pima - Virginia G. Piper Cancer Care Network, Scottsdale, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute, Little Rock, Arkansas, United States
A Study Investigating the Absolute Oral Bioavailability of Balovaptan After Single and Multiple Daily Oral Doses of Balovaptan in Healthy Volunteers
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT03764449
- Locations
- 🇳🇱
Pra International Group B.V, Groningen, Netherlands
A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 55
- Registration Number
- NCT03762681
- Locations
- 🇵🇱
ID Clinic, Myslowice, Poland
🇰🇷Asan Medical Center., Seoul, Korea, Republic of
🇭🇰Queen Mary Hospital, Hong Kong, Hong Kong
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 899
- Registration Number
- NCT03761849
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇵🇱Krakowska Akademia Neurologii Sp z o.o. Centrum Neurologii K, Krakow, Poland
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 438
- Registration Number
- NCT03735121
- Locations
- 🇨🇱
James Lind Centro de Investigación Del Cáncer, Temuco, Chile
🇨🇱ONCOCENTRO APYS; Oncología, Vina Del Mar, Chile
🇬🇹INTEGRA Cancer Institute, Ciudad de Guatemala, Guatemala
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 454
- Registration Number
- NCT03726879
- Locations
- 🇺🇸
Tennessee Oncology - Nashville, Nashville, Tennessee, United States
🇺🇸HCA Midwest Division, Kansas City, Missouri, United States
🇺🇸New York University Medical Center PRIME; NYU Langone Medical Center, New York, New York, United States
A Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT03717064
- Locations
- 🇺🇸
Covance Research Unit - Daytona, Daytona Beach, Florida, United States
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 134
- Registration Number
- NCT03708328
- Locations
- 🇪🇸
Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain
🇳🇿Auckland City Hospital; Clinical Oncology, Auckland, New Zealand
🇪🇸START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid, Spain
A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-10-04
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 77
- Registration Number
- NCT03695380
- Locations
- 🇺🇸
Medical College of Georgia; Obstetrics & Gynecolog, Augusta, Georgia, United States
🇺🇸Stephenson Cancer Center Investigational Pharmacy, Oklahoma City, Oklahoma, United States
🇺🇸Florida Hospital Cancer Institute; Clinical Research Department, Orlando, Florida, United States
A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT03693573